We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Ipsen SA (PK) | USOTC:IPSEY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.86 | -5.52% | 31.84 | 31.05 | 33.32 | 31.84 | 31.84 | 31.84 | 395 | 21:14:28 |
From Jun 2019 to Jun 2024
By Inti Landauro
PARIS--French pharmaceutical giant Sanofi (SAN.FR) agreed to sell a portfolio of five drugs in Europe to smaller local rival Ipsen (IPN.FR) for 83 million euros ($88 million) to help pave the way for Sanofi to take over certain assets from Germany's Boehringer Ingelheim GmbH.
Under the deal, Ipsen will buy the rights to market an analgesic, an antispasmodic, a laxative and two expectorants in eight European countries, though the manufacturing will be provided by third parties, the company said Monday in a news release.
Ipsen said it would finance the acquisition with its existing cash and lines of credit.
The asset sale is a result of requirements imposed by the European Commission in connection with Sanofi's deal to exchange its animal-health business for most of Boehringer Ingelheim's consumer health-care unit.
Ipsen said it would finance the acquisition of the Sanofi assets with its own cash.
Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
February 13, 2017 02:13 ET (07:13 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Ipsen (PK) Chart |
1 Month Ipsen (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
